Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

• Status: Completed
• Trial end date: 2019-11-14

Summary

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

• Phase: Phase 1

Details

• Lead Sponsor: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Durvalumab; Etoposide; Fluorouracil; Folic Acid; Gemcitabine; Leucovorin; Levoleucovorin; Oxaliplatin; Paclitaxel; Tremelimumab